• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Record of Telephone Conversation - Agriflu, July 9, 2009

System Info - 106872 MCWATTERS, BERNARD 05-Oct-2009 14:47:14 MCWATTERS

RECORD OF TELEPHONE CONVERSATION

Submission Type: Original Application Submission ID: 125297/0 Office: OVRR

Product:
Influenza Vaccine

Applicant:
Novartis Vaccines and Diagnostics, Inc.

Telecon Date/Time: 09-JUL-2009 12:00 AM Initiated by FDA? Yes
Telephone Number:

Communication Categorie(s):
Information Request

Author: BERNARD MCWATTERS

Telecon Summary:
Question regarding the outstanding inspectional issues.

FDA Participants: Bernard McWatters

Non-FDA Participants: Joanne Totosy de Zepetnek

Trans-BLA Group: No

Related STNs: None

Related PMCs: None

Telecon Body:
From: McWatters, Bernard [mailto:Bernard.McWatters@fda.hhs.gov]
Sent: Thursday, July 09, 2009 2:54 PM
To: Totosy de Zepetnek, Joanne
Cc: Cheung, Anissa; Olin, Rebecca
Subject: RE: Summary of July 6, 2009 discussion re Agrippal BLA 125297 Complete Response
Joanne,
I just had a chance to speak with Rebecca and Anissa about your outstanding inspectional issues. For issue 1: In the cover letter to your complete response, you indicated that you could submit the hold time validation data in July 2009. Why is this not happening? Have you not been able to produceb(4)lots of the B strain? If you have,then you should have hold time data to submit. Issue 2: Rebecca asked me why it would take you this long to perform a cleaning validation study of the inoculation machine? With the production at this time, you should constantly be using and cleaning this machine, so cleaning validation data should not take too long to get during production, unless there is a problem. Is there a problem? Please send me clarifications to these points so that we can make an informed decision about allowing them to be post marketing commitments. Rebecca is still in the process of reviewing the -b(4)- filling line data and did not have any comments at this time regarding that issue.
JP
Bernard J.P. McWatters, Ph.D.
FDA/CBER/OVRR/DVRPA
HFM-478
1401 Rockville Pike rm. 379N
Rockville, MD 20852
Office - 301-827-3921